<DOC>
	<DOCNO>NCT00689169</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety preparative regimen utilize standard-dose Yttrium-90 Ibritumomab Tiuxetan ( Zevalin ) radioimmunotherapy combine high-dose BEAM follow ASCT first line treatment patient age 18 65 year poor prognosis CD 20 Diffuse Large B-Cell lymphoma</brief_summary>
	<brief_title>Targeted Intensification Utilizing ZBEAM Followed Autologous Stem Cell Transplantation ( ASCT ) Patients With High-grade B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Aged 18 65 year . Patient pathologically proven , high grade Bcell Lymphoma CD 20 positive ( WHO classification ) : Diffuse large B cell lymphoma . Adverse prognostic factor IPI &gt; 1 In Complete Remission , partial response first line treatment . Previously treat chemotherapy regimen contain rituximab : R CHOP R ACVBP Chemosensitive disease PET Scan prior transplant Eligible autologous stem cell transplantation With minimum life expectancy 3 month . Negative HIV , HBV HCV serology ( last 4 week except vaccination ) . Having previously sign write informed consent . Histological transformation diffuse large B cell lymphoma , type low grade lymphoma More one line treatment . Prior transplantation . Prior exposure Zevalin Central nervous system meningeal involvement lymphoma . Contraindication drug contain chemotherapy regimen . Any serious active disease comorbid medical condition ( accord investigator 's decision information provide IDB ) . Poor renal function ( creatinin level 2.5 maximum normal level ) unless abnormality relate lymphoma . Poor hepatic function ( total bilirubin level 30 micro mol/l , transaminases 2.5 maximum normal level ) unless abnormality relate lymphoma . Poor bone marrow reserve define neutrophils less 1.5 G/l platelet le 100 G/l Large bone marrow irradiation 40percent . Bone marrow infiltration Lack sufficient autologous hematopoietic stem cell transplantation . Prior treatment murine antibody Known hypersensibility murine antibody proteins Any history cancer last 5 year , exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma . Treatment investigational drug within 30 day plan first cycle chemotherapy study . Adult patient unable give inform consent intellectual impairment . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma Diffuse</keyword>
	<keyword>B-Cell lymphoma</keyword>
	<keyword>Aggressive lymphoma</keyword>
</DOC>